Related Experiment Videos
[Immunotolerance of RU 41740].
1Unité de Recherches sur la Pathologie autoimmune (INSERM U283), Hôpital Cochin, Paris.
Presse Medicale (Paris, France : 1983)
|July 27, 1988
Summary
RU 41740, an organic immunomodulator, shows excellent safety for preventing recurrent respiratory infections in children and adults. Clinical trials confirmed no adverse effects on immunological markers or overall health in both animal models and human subjects.
Area of Science:
- Immunology
- Pharmacology
Background:
- Recurrent respiratory infections pose a significant health burden in both pediatric and adult populations.
- Immunomodulators offer a potential preventive strategy for managing these infections.
Purpose of the Study:
- To evaluate the immunological safety and tolerability of RU 41740, an organic immunomodulator.
- To assess the preventive efficacy of RU 41740 against recurrent respiratory infections.
Main Methods:
- Immunological safety was assessed in NZB-NZW mice, a model for lupus erythematosus.
- Clinical safety and tolerability were evaluated in human adults and children, including atopic subjects.
- Comprehensive immunological parameters were monitored pre- and post-treatment in human participants.
Main Results:
- RU 41740 did not alter survival rates or urinary protein excretion in NZB-NZW mice.
- The compound was well tolerated clinically in adult mice, their offspring, and human subjects.
- No pathological changes were observed in a wide range of immunological markers in humans, including blood counts, immunoglobulins, complement, and autoantibodies.
Conclusions:
- RU 41740 demonstrates a favorable safety profile for preventive use against recurrent respiratory infections.
- The immunomodulator is well-tolerated in both pediatric and adult populations, including those with atopic conditions.
- Further clinical studies are warranted to confirm its preventive efficacy.